Expression of hypoxia inducible factor-1α (HIF-1α) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: Difference in hypoxic status depending on histological character

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 111-116

  Yasuda, Masanori ^a   Miyazawa, Masaki ^b   Fujita, Mariko ^b   Kajiwara, Hiroshi ^b   Iida, Tetsuji ^b   Hirasawa, Takeshi ^b   Muramatsu, Toshinari ^b   Murakami, Masaru ^b   Mikami, Mikio ^b   Saitoh, Kaoru ^c   Shimizu, Michio ^a   Takekoshi, Susumu ^b   Osamura, R Yoshiyuki ^b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; GLUT 1; HIF 1 ; Hypoxia; Ovary

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROENVIRONMENT; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 38749098610     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.111     Document Type: Article

References (27)

1. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
2. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: 62-67, 2002.
3. 2-dependent degradation domain via the ubiquitine-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
4. Younes M, Lechago LV and Lechago J: Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 2: 1151-1154, 1996.
5. Wheeler TJ and Hinkle PC: The glucose transporter of mammalian cells. Annu Rev Physiol 47: 503-517, 1985.
6. Froehner SC, Davies A, Baldwin SA and Lienhard GE: The blood-nerve barrier is rich in glucose transporter. J Neurocytol 17: 173-178, 1988.
7. Pardridge WM, Boado RJ and Farrell CR: Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative Western blotting and in situ hybridization. J Biol Chem 265: 18035-18040, 1990.
8. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC and Golde DW: Vitamin C crosses the blood-brain barrier in the oxidized from through the glucose transporters. J Clin Invest 100: 2842-2848, 1997.
9. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A and Burstein DE: GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83: 34-40, 1998.
10. Ogawa J, Inoue H and Koide S: Glucose-transporter-type-I-gene amplification correlates with sialy1-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 74: 189-192, 1997.
11. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadgi M, Angioli R, Penalver M, Mancuso S and Scambia G: GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92: 1144-1150, 2001.
12. Kuwamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K and Suzuki T: Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92: 634-641, 2001.
13. Kalir T, Wang BY, Goldfischer M, Haber RS, Reder I, Demopoulos R, Cohen CJ and Burstein DE: Immunohistochemistry staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 94: 1078-1082, 2002.
14. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC and Harris AL: Hypoxia inducible factor (HLF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61: 1830-1832, 2001.
15. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH and Semenza GL: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
16. Birner P, Schindl M, Obermair A, Breitenecker G and Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7: 1661-1668, 2001.
17. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000.
18. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ and van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93: 309-314, 2001.
19. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW and Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2018, 2000.
20. Ikeda E: Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int 55: 603-610, 2005.
21. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C and Burstein DE: Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 88: 2774-2781, 2000.
22. Haber RS, Weiser KR, Pritsker A, Reder I and Burstein DE: GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 7: 363-367, 1997.
23. Younes M, Lechago LV and Lechago J: Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 2: 1151-1154, 1996.
24. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T and Osamura Y: Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep 14: 1499-1504, 2005.
25. Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, Yoshikawa T, Tsuburaya A, Ito T and Satoh S: Supression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Left 154: 175-182, 2000.
26. Cantuaria G, Magalhaes A, Penalver M, Angioli R, Braunschweiger P, Gomez-Marin O, Kanhoush R, Gomez-Fernandez C and Nadji M: Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol 79: 33-37, 2000.
27. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ and Abraham RT: Regulation of hypoxia-inducible factor 1alpha expression and function by mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002.